Valneva has reported the latest positive antibody persistence data from its Study VLA1553-303 of a single dose of chikungunya vaccine, IXCHIQ.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,